Literature DB >> 27485455

Clinical characteristics and risk factors of Intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation.

Xiao-Hui Zhang1, Qian-Ming Wang1, Huan Chen1, Yu-Hong Chen1, Wei Han1, Feng-Rong Wang1, Jing-Zhi Wang1, Yuan-Yuan Zhang1, Xiao-Dong Mo1, Yao Chen1, Yu Wang1, Ying-Jun Chang1, Lan-Ping Xu1, Kai-Yan Liu1, Xiao-Jun Huang2.   

Abstract

Intracranial hemorrhage (ICH) is one of the most life-threatening neurological complications after allogeneic hematopoietic stem cell transplantation. Although cerebral complications and its causes after allo-HSCT are well documented, assessment of the incidence and risk factors of intracranial hemorrhage following allo-HSCT are less discussed. A nested case-control study was conducted involving 160 subjects drawn from 2169 subjects who underwent HSCT at Peking University People's Hospital between 2004 and 2014. Thirty-two patients (1.5 %) with ICH were identified, and 128 controls were matched for age, gender, transplantation type, and time of transplantation. Intracranial hemorrhage was identified by CT scan and/or MRI by searching hospital records. Among the 32 ICH patients, 27 (82.9 %) developed intraparenchymal hemorrhages (IPH), 2 cases (5.7 %) suffered subdural hematomas (SDH), and 3 cases (8.6 %) had multiple hemorrhage lesions in the brain parenchyma. The median time of appearance for cerebral hemorrhages was 147.5 days. Multivariate analysis showed that systemic infections (hazard ratio 2.882, 95 % confidence interval 1.231-6.746), platelet count (5.894, 1.145-30.339), and fibrinogen levels (3.611, 1.528-8.532) were independent risk factors for intracranial hemorrhage among HSCT patients. The cumulative survival rate in the intracranial hemorrhage and control groups were 43.3 and 74.7 % (P = .001), respectively. Intracranial hemorrhage is associated with high mortality and a decreased overall survival rate. Systemic infections, platelet count, and fibrinogen levels were individual independent risk factors.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; Fibrinogen; Intracranial hemorrhage; Thrombocytopenia

Mesh:

Substances:

Year:  2016        PMID: 27485455     DOI: 10.1007/s00277-016-2767-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  10 in total

1.  Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact.

Authors:  M R Dowling; S Li; B R Dey; S L McAfee; H R Hock; T R Spitzer; Y-B Chen; K K Ballen
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

2.  Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation.

Authors:  Xiying Ren; Qiusha Huang; Qingyuan Qu; Xuan Cai; Haixia Fu; Xiaodong Mo; Yu Wang; Yawei Zheng; Erlie Jiang; Yishan Ye; Yi Luo; Shaozhen Chen; Ting Yang; Yuanyuan Zhang; Wei Han; Feifei Tang; Wenjian Mo; Shunqing Wang; Fei Li; Daihong Liu; Xiaoying Zhang; Yicheng Zhang; Shuqing Feng; Feng Gao; Hailong Yuan; Dao Wang; Dingming Wan; Huan Chen; Yao Chen; Jingzhi Wang; Yuhong Chen; Ying Wang; Kailin Xu; Tao Lang; Xiaomin Wang; Hongbin Meng; Limin Li; Zhiguo Wang; Yanling Fan; Yingjun Chang; Lanping Xu; Xiaojun Huang; Xiaohui Zhang
Journal:  Blood Adv       Date:  2021-12-14

Review 3.  Cancer and stroke: commonly encountered by clinicians, but little evidence to guide clinical approach.

Authors:  Malin Woock; Nicolas Martinez-Majander; David J Seiffge; Henriette Aurora Selvik; Annika Nordanstig; Petra Redfors; Erik Lindgren; Mayte Sanchez van Kammen; Alexandros Rentzos; Jonathan M Coutinho; Karen Doyle; Halvor Naess; Jukka Putaala; Katarina Jood; Turgut Tatlisumak
Journal:  Ther Adv Neurol Disord       Date:  2022-06-28       Impact factor: 6.430

4.  Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation.

Authors:  Xuan Cai; Hai-Xia Fu; Xiao-Dong Mo; Yu Wang; Yuan-Yuan Zhang; Jin Wu; Wei Han; Fei-Fei Tang; Ruo-Yun Gui; Huan Chen; Yao Chen; Peng Zhao; Chen-Hua Yan; Jing-Zhi Wang; Yu-Hong Chen; Ying-Jun Chang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Bone Marrow Transplant       Date:  2020-04-24       Impact factor: 5.483

5.  [Chinese expert consensus on the diagnosis and treatment of venous thromboembolism after hematopoietic stem cell transplantation (2022)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-03-14

Review 6.  Neurological complications of hematopoietic cell transplantation in children and adults.

Authors:  Adriana Octaviana Dulamea; Ioana Gabriela Lupescu
Journal:  Neural Regen Res       Date:  2018-06       Impact factor: 5.135

7.  Neurologic complications after allogeneic transplantation: a meta-analysis.

Authors:  Maria Gavriilaki; Maria Mainou; Eleni Gavriilaki; Anna-Bettina Haidich; Sotirios Papagiannopoulos; Ioanna Sakellari; Achilles Anagnostopoulos; Vasilis Kimiskidis
Journal:  Ann Clin Transl Neurol       Date:  2019-09-27       Impact factor: 4.511

8.  Elevated blood urea nitrogen is associated with recurrence of post-operative chronic subdural hematoma.

Authors:  Ning Wang; Jiangnan Hu; Anthony Oppong-Gyebi; Xuanhao Zhu; Yihao Li; Jianjing Yang; Linhui Ruan; Qichuan Zhuge; Sheng Ye
Journal:  BMC Neurol       Date:  2020-11-10       Impact factor: 2.474

9.  Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia - a nested case-control study.

Authors:  Loes L Cornelissen; Aukje L Kreuger; Camila Caram-Deelder; Rutger A Middelburg; Jean Louis H Kerkhoffs; Peter A von dem Borne; Erik A M Beckers; Karen M K de Vooght; Jürgen Kuball; J J Zwaginga; Johanna G van der Bom
Journal:  Ann Hematol       Date:  2020-10-17       Impact factor: 3.673

Review 10.  Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Zhuo Wang; Munan Zhao; Sujun Gao
Journal:  Front Neurol       Date:  2021-07-16       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.